Biotech: Page 2
-
Courtesy of Vertex Pharmaceuticals
Vertex moves kidney disease drug into late-stage testing
The drug, inaxaplin, is an important pipeline prospect for Vertex, which is working to expand beyond the cystic fibrosis medicines that made its name.
By Delilah Alvarado • April 1, 2024 -
maciek905 via Getty Images
Emerging biotechBoundless Bio breaks IPO lull with $100M fundraise
The startup’s performance will test investors’ appetite for early-stage drugmakers, as Boundless has only advanced as far as Phase 1 clinical trials.
By Gwendolyn Wu • March 28, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.
By BioPharma Dive staff -
Permission granted by Gilead Sciences
Gilead bets on Xilio cancer drug as biotech restructures
Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.
By Ned Pagliarulo • March 28, 2024 -
Permission granted by Art Krieg
Emerging biotechBiotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Dive.
By Ben Fidler • March 28, 2024 -
Maddie Meyer via Getty Images
Moderna gets Blackstone backing for flu vaccine R&D
An arm of the private equity firm pledged up to $750 million to support Moderna’s development of its mRNA technology for influenza shots.
By Delilah Alvarado • March 27, 2024 -
Michael M. Santiago via Getty Images
Obesity drugsViking stays in obesity drug race with early data for weight loss pill
The results are from a small Phase 1 study, but suggest Viking’s oral GLP-1 drug may not come with high rates of gastrointestinal side effects.
By Jonathan Gardner • March 26, 2024 -
Elizabeth Regan / Industry Dive
Stoke shares surge on updated results for Dravet drug
The biotech is trying to develop a Spinraza-like drug for the condition, a form of genetic epilepsy. Fresh data appear supportive of a high dose’s effectiveness.
By Ned Pagliarulo • March 26, 2024 -
Permission granted by Portal Bio
Q&ASQZ, Portal founder Armon Sharei on starting over in biotech
“I still care way too much about cell therapies,” said Sharei, weeks after his former startup, SQZ Biotechnologies, was liquidated.
By Gwendolyn Wu • March 26, 2024 -
Courtesy of AbbVie
AbbVie to buy immune drug developer Landos
Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.
By Delilah Alvarado • March 25, 2024 -
hapabapa via Getty Images
Novo to acquire heart failure drug in $1B deal for Cardior
Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.
By Ned Pagliarulo • March 25, 2024 -
sanjeri via Getty Images
Sponsored by Quest DiagnosticsThe future of companion diagnostic (CDx) development: Why commercialization is key
As precision medicine expands into a growing number of therapeutic areas, the “one size fits all” approach to drug development is becoming less common.
March 25, 2024 -
Sarah Silbiger via Getty Images
FDA clears first-of-its-kind Duchenne drug for broad use
The approval of Italfarmaco’s Duvyzat is the first for an oral, non-steroidal Duchenne drug and was issued for all patients at least six years of age, regardless of their genetic underpinnings.
By Ben Fidler • March 22, 2024 -
cagkansayin via Getty Images
NextCure to lay off 37% of staff, dial back research plans
The job cuts at the cancer biotech will primarily impact manufacturing roles, but will touch on several other parts of the organization too, the company said.
By Delilah Alvarado • March 21, 2024 -
Permission granted by Mirador Therapeutics
Emerging biotechMirador debuts with $400M, picking up where immune drugmaker Prometheus left off
The financing for the startup, which is led by former executives of a biotech Merck recently bought for nearly $11 billion, is the sector’s largest for a privately held company this year.
By Gwendolyn Wu • March 21, 2024 -
Nemes Laszlo via Getty Images
Emerging biotechCapstan heats up ‘in vivo’ cell therapy chase with $175M fundraise
The high-profile startup, co-founded by CAR-T innovator Carl June, will use the funds to bring an autoimmune disease treatment into proof-of-concept studies.
By Ben Fidler • March 20, 2024 -
Peddalanka Ramesh Babu via Getty Images
Emerging biotechClasp launches with $150M and a plan for precision cancer immunotherapies
The company claims its approach could yield more effective and safer T-cell engagers, a type of cancer medicine that’s attracted significant interest from drugmakers in recent years.
By Gwendolyn Wu • March 20, 2024 -
nopparit via Getty Images
Engrail’s precision psychiatry drugs get more buy in from venture investors
The San Diego-based startup added $157 million in new funding to back a drug for generalized anxiety order that’s now in human testing.
By Jacob Bell • March 19, 2024 -
Permission granted by Bluebird bio
Bluebird, short on cash, takes on $175M in debt financing
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.
By Delilah Alvarado • March 18, 2024 -
shutterstock.com/VAlekStudio
Sponsored by VeevaGive HCPs a proactive way to reach your field team: Add inbound
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024 -
PeopleImages via Getty Images
Sponsored by Cardinal Health Sonexus™ Access and Patient SupportThe digital divide: Balancing automation and human interaction regardless of the patient support program model
Balancing automated patient support with human touch is key in healthcare. Hybrid models offer a pragmatic path forward, prioritizing patient-centricity.
March 18, 2024 -
JaysonPhotography via Getty Images
Contineum, a startup born from a Roche buyout, files for IPO
The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.
By Ben Fidler • March 17, 2024 -
Courtesy of Madrigal Pharmaceuticals
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
By Ben Fidler • March 15, 2024 -
Love Employee via Getty Images
German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing
The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.
By Gwendolyn Wu • March 14, 2024 -
Permission granted by Novartis
Emerging biotechIFM, an unorthodox biotech startup, scores third buyout with Novartis deal
With a decision by the Swiss pharma to acquire another one of its subsidiaries, IFM Therapeutics has now sold three spin-offs for a total of $700 million upfront and the potential for billions more in future payments.
By Kristin Jensen • March 13, 2024 -
Nemes Laszlo via Getty Images
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
The partnership is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
By Ben Fidler • March 12, 2024
Previous
